1. Search Result
Search Result
Results for "

influenza A virus

" in MedChemExpress (MCE) Product Catalog:

292

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

27

Peptides

6

Inhibitory Antibodies

53

Natural
Products

5

Recombinant Proteins

21

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131179

    Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .
    Influenza A virus-IN-1
  • HY-112543

    Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV) .
    S119-8
  • HY-131069A

    Influenza Virus Infection
    MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC90 of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains .
    MBX2329
  • HY-149034

    S5

    Influenza Virus Infection Cancer
    Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
    Influenza A virus-IN-8
  • HY-146004

    Influenza Virus Infection
    Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of neuraminidase. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses .
    Influenza A virus-IN-4
  • HY-162492

    Influenza Virus Infection
    Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC50 of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC50 of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .
    Influenza A virus-IN-14
  • HY-W892911

    Influenza Virus Infection
    AV-5080 is an orally active neuraminidase inhibitor. AV-5080 can be used for the research of influenza A and B viruses .
    AV-5080
  • HY-123304

    Influenza Virus Infection
    MBX2546 is a influenza A virus inhibitor with the Kd values of 5.3μM and > 100 μM for H1 Hemagglutinin and H3 Hemagglutinin, respectively .
    MBX2546
  • HY-144066

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
    Cap-dependent endonuclease-IN-21
  • HY-144067

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .
    Cap-dependent endonuclease-IN-23
  • HY-P99750

    CT-P23

    Influenza Virus Infection
    Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
    Navivumab
  • HY-143495

    RSV Influenza Virus Infection
    RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM) .
    RSV-IN-3
  • HY-143496

    RSV Influenza Virus Infection
    RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM) .
    RSV-IN-4
  • HY-P5643

    Bacterial Infection
    Retrocyclin-2 is an antimicrobial peptide against human immunodeficiency virus, influenza A and herpes simplex virus .
    Retrocyclin-2
  • HY-P5644

    Bacterial Infection
    Retrocyclin-3 is an antimicrobial peptide against human immunodeficiency virus, influenza A and herpes simplex virus .
    Retrocyclin-3
  • HY-143766

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .
    Cap-dependent endonuclease-IN-13
  • HY-161820

    Influenza Virus Infection
    IAV-IN-3 (Compound (R,S)-16s) is an anti-influenza A virus (IAV) agent (EC50 = 0.134 μM) with weak cytotoxicity (CC50 = 15.35 μM for MDCK cells). IAV-IN-3 inhibits IAV polymerase with an IC50 of 0.045 μM .
    IAV-IN-3
  • HY-143744

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
    Cap-dependent endonuclease-IN-3
  • HY-W011518

    Influenza Virus Infection
    2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation .
    2′-Deoxy-2′-fluoroguanosine
  • HY-157249

    Influenza Virus Infection
    Antiviral agent 43 (compound 16) is a potent and orally active influenza A viruses entry inhibitor. Antiviral agent 43 inhibits replications of influenza A strains VH04-H5N1 and PR8-H1N1 with EC50s of 240 nM and 72 nM, respectively .
    Antiviral agent 43
  • HY-N7346

    HSV Cholinesterase (ChE) Infection
    Lucidadiol is a natural compound isolated from Ganoderma lucidum. Lucidadiol exhibits acetylcholinesterase-inhibitory activity, with IC50 values of 31 μM. Lucidadiol shows antiviral activity against influenza virus type A and HSV type 1 .
    Lucidadiol
  • HY-N0035
    Arctigenin
    5+ Cited Publications

    (-)-Arctigenin

    MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin
  • HY-158312

    Necroptosis RIP kinase Influenza Virus Infection Inflammation/Immunology
    UH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury .
    UH15-38
  • HY-N0035R

    MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin (Standard)
  • HY-143743

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .
    Cap-dependent endonuclease-IN-2
  • HY-143755

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .
    Cap-dependent endonuclease-IN-9
  • HY-134922

    Influenza Virus Infection
    NS1-IN-1 (compound 3) is a potent NS1 inhibitor. NS1 is a major influenza A virus virulence factor that inhibits host gene expression. NS1-IN-1 decreases viral protein levels, contributing to the reduction of virus replication. NS1-IN-1 shows antiviral activity by repressing the activity of mTORC1 in a TSC1-TSC2-dependent manner .
    NS1-IN-1
  • HY-N12110

    Toll-like Receptor (TLR) SARS-CoV Infection
    SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .
    SMU-CX1
  • HY-162701

    SARS-CoV Influenza Virus RSV HSV Infection
    Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2 .
    Antiviral agent 58
  • HY-161454

    Virus Protease Influenza Virus SARS-CoV Infection
    Antiviral agent 54 (compound 33) is a broad-spectrum and orally active antiviral agent. Antiviral agent 54 shows antiviral activity for ZIKV, HCoV-OC43 and influenza A virus (IVA). Antiviral agent 54 decreases the ZIKV RNA and protein level .
    Antiviral agent 54
  • HY-B1537

    2',3',5'-Tri-O-acetyl-6-azauridine

    Virus Protease Influenza Virus Infection Inflammation/Immunology
    Azaribine (2',3',5'-Tri-O-acetyl-6-azauridine) is a potent orotidine monophosphate decarboxylase (OMPD) inhibitor. Azaribine is an antiviral inhibitor of several RNA viruses and inhibits viral genome replication and gene transcription. Azaribine shows broad-spectrum antiviral activity (EC50=3.80 nM-1.73 μM against influenza A and B viruses; EC50=1.62 μM against ZIKV Paraiba). Azaribine, a triacetate salt of Azauridine, has the potential for psoriasis research .
    Azaribine
  • HY-143494

    RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
    RSV/IAV-IN-3
  • HY-143492

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-1 (compound 14) is a potent influenza A virus inhibitor with an EC50 of 2.46 µM and CC50 of >200 µM. Influenza virus-IN-1 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 312.36 nM. Influenza virus-IN-1 shows shows anti-influenza A virus activities .
    Influenza virus-IN-1
  • HY-155476

    Influenza Virus Infection
    Influenza virus-IN-8 (compound A4) is an inhibitor of influenza virus (Influenza Virus) that induces viral nucleoprotein (NP) aggregation and prevents its nuclear accumulation. Influenza virus-IN-8 has broad-spectrum anti-influenza activity and can inhibit the replication and transcription of influenza A virus. Influenza virus-IN-8 also inhibits Oseltamivir (HY-13317)-resistant H1N1/pdm09 strains .
    Influenza virus-IN-8
  • HY-143493

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-2 (compound 19) is a potent influenza virus inhibitor with an EC50 of 2.58 µM and CC50 of 150.85 µM. Influenza virus-IN-2 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 489.39 nM. Influenza virus-IN-2 shows shows anti-influenza A virus activities .
    Influenza virus-IN-2
  • HY-P99620

    CT-P22; CT120

    Influenza Virus Infection
    Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
    Firivumab
  • HY-P1857

    Influenza Virus Infection
    CEF7, Influenza Virus NP (380-388) is a HLA-B *08 restricted influenza virus nucleoprotein epitope. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .
    CEF7, Influenza Virus NP (380-388)
  • HY-146147

    Influenza Virus Infection
    Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC50 of 1 nM against influenza A/H3N2 virus .
    Influenza virus-IN-5
  • HY-132286

    Others Infection
    2-PADQZ is an antiviral compound with activity against influenza viruses. 2-PADQZ specifically binds to the influenza A virus RNA promoter and forms a binding site at the internal loop. 2-PADQZ has a significant inhibitory effect on H1N1 and H3N2 influenza A viruses and influenza B viruses .
    2-PADQZ
  • HY-14818A

    CS-8958

    Influenza Virus Infection
    Laninamivir octanoate (CS-8958), a proagent of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses .
    Laninamivir octanoate
  • HY-14818C

    CS-8958 hydrate

    Influenza Virus Infection
    Laninamivir octanoate hydrate (CS-8958 hydrate), a prodrug of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate hydrate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses .
    Laninamivir octanoate hydrate
  • HY-W019823

    Fluorescent Dye Infection Neurological Disease
    4-MUNANA is a fluorescent substrate used for neuraminidase activity assay .
    4-MUNANA
  • HY-P5550

    Influenza Virus Infection
    Urumin has antiviral activity against the human influenza A virus. Urumin inhibits the growth of PR8 influenza virus (IC50: 3.8 μM). Urumin targets the conserved stalk of H1 hemagglutini, and is effective at neutralizing drug-resistant H1 influenza viruses. Urumin protects naive mice from lethal influenza infection .
    Urumin
  • HY-P1835

    Influenza Virus Inflammation/Immunology
    CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B *2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity .
    CEF8, Influenza Virus NP (383-391)
  • HY-155110

    Influenza Virus Infection
    Antiviral agent 34 is a potent and orally active antiviral agent against influenza A and B subtypes with an EC50 value of 0.8 nM for H1N1 proliferation. Antiviral agent 34 derivatives inhibited influenza virus proliferation by targeting influenza virus RNA-dependent RNA polymerase. Antiviral agent 34 can be used for influenza virus research .
    Antiviral agent 34
  • HY-156288

    Influenza Virus Infection
    Anti-Influenza agent 5 (Compound IIB-2), chalcone-like derivative, is an influenza nuclear export inhibitor. Anti-Influenza agent 5 has inhibitory effects on oseltamivir-resistant strains. Anti-Influenza agent 5 can impede virus proliferation by blocking the export of influenza virus nucleoprotein .
    Anti-Influenza agent 5
  • HY-P1749

    Influenza Virus Infection
    Influenza HA (307-319) is 13 amino acids 307 to 319 fragment of Influenza HA. Influenza HA is a glycoprotein found on the surface of influenza viruses .
    Influenza HA (307-319)
  • HY-146001

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-4 (compound 11e) is a potent influenza virus neuraminidase inhibitor with IC50s of 3.4, 0.094, 0.79, 0.077 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-4 shows NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-4 shows low cytotoxicity with an CC50 of >200 µM. Influenza virus-IN-4 shows no obvious toxicity at the dose of 1500 mg/kg in mice .
    Influenza virus-IN-4
  • HY-P0289

    Influenza Virus Infection
    CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.
    CEF3
  • HY-N2216

    Onjisaponin F

    Influenza Virus Infection
    Polygalasaponin XXXI (Onjisaponin F) is an effective adjuvant for intranasal administration of influenza Influenza hemagglutinin (HA) vaccine to protect influenza virus infection .
    Polygalasaponin XXXI

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: